SCHEMBL7143078

SCHEMBL7143078

OC[C@@H]1OC(OCc2ccccc2)[C@@H](O)[C@@H]1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.58
SYNJ2 O15056 2/20 0.54
KDM4E B2RXH2 1/20 0.54
ABL1 P00519 1/20 0.54
ALPL P05186 1/20 0.54
POLB P06746 1/20 0.54
ALPI P09923 1/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54
ALPG P10696 1/20 0.54
PABPC1 P11940 1/20 0.54
RECQL P46063 1/20 0.54
GALK1 P51570 1/20 0.54
CASP7 P55210 1/20 0.54
CASP6 P55212 1/20 0.54
MCL1 Q07820 1/20 0.54
RIN1 Q13671 1/20 0.54
EIF4H Q15056 1/20 0.54
SLC5A2 P31639 1/20 0.52
TYR P14679 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3046506 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL
SCHEMBL6859149 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL
SCHEMBL4318187 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL
SCHEMBL3046511 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL
SCHEMBL6873291 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL
SCHEMBL8727122 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL
SCHEMBL6367492 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL
SCHEMBL5032458 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL
SCHEMBL5032455 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL
SCHEMBL6865171 1.00 SLC6A2 (0.58) SLC6A2SYNJ2KDM4EABL1ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027359-B9 MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF RIBAPHARM INC (US) 2003-09-17 EP disclosed
EP-1027359-B1 MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND USES THEREOF RIBAPHARM INC (US) 2003-04-23 EP disclosed
US-6552183-B1 Moncyclic L-nucleosides analogs ICN PHARMACEUTICALS, INC. 2003-04-22 US disclosed
EP-1302474-A1 Monocyclic L-nucleosides, analogs and uses thereof Ribapharm, Inc. (US) 2003-04-16 EP disclosed
US-20030018186-A1 Monocyclic L-nucleosides, analogs and uses thereof BAUSCH HEALTH COMPANIES INC. (CA) 2003-01-23 US disclosed
EP-1254911-A1 Monocyclic L-nucleosides, analogs and uses thereof ICN Pharmaceuticals, Inc. (US) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018186-A1 Monocyclic L-nucleosides, analogs and uses thereof PNP, TYMP, SLC29A1 SLC6A2 2118/4885SYNJ2 3247/4885KDM4E 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.